<DOC>
	<DOCNO>NCT00659568</DOCNO>
	<brief_summary>RATIONALE : Metformin temsirolimus may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose metformin give together temsirolimus treat patient metastatic unresectable solid tumor lymphoma .</brief_summary>
	<brief_title>Metformin Temsirolimus Treating Patients With Metastatic Unresectable Solid Tumor Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose recommended phase II dose metformin hydrochloride administer temsirolimus patient advance solid cancer lymphoma . Secondary - To determine toxicity safety , particular reference glucose lipid deregulation , regimen patient . - To assess antitumor activity , include tumor response rate time progression , patient treat regimen . OUTLINE : This dose-escalation study metformin hydrochloride . Patients receive oral metformin , twice , three time daily day 1-28 temsirolimus IV 30-60 minute day 1 , 8 , 15 , 22 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy , include follow type : Renal cell Endometrial Breast Small cell lung carcinoma Lymphoma Metastatic unresectable disease standard curative palliative measure exist longer effective Measurable disease accord RECIST criterion No unstable primary CNS tumor metastases PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy &gt; 12 week Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L AST ≤ 2.5 time upper limit normal ( ULN ) Serum creatinine ≤ ULN Serum bilirubin ≤ 1.5 time ULN Negative pregnancy test Fertile patient must use effective contraception Able understand willing sign write informed consent document Exclusion criterion : Allergies history allergic reaction attribute compound similar chemical biologic composition temsirolimus metformin Diabetes mellitus ( type I II ) Uncontrolled hypertriglyceridemia ( triglyceride level &gt; 10 mmol/L ) History lactic acidosis Inability swallow digest oral medication Uncontrolled intercurrent illness include , limited , follow : Uncontrolled hypertension Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement Significant traumatic injury within 21 day prior treatment PRIOR CONCURRENT THERAPY : Inclusion criterion : Recovered prior therapy At least 4 week since prior chemotherapy radiotherapy ( 6 week carmustine mitomycin C ) except lowdose , nonmyelosuppressive radiotherapy No limitation prior therapy Concurrent lowdose anticoagulant ( i.e. , warfarin ) allow provide INR ≤ 1.1 time ULN Concurrent fulldose anticoagulant ( i.e. , warfarin ) allow provide INR within institutional therapeutic range ( usually 2.03.0 ) Exclusion criterion : Major surgery within past 21 day Prior temsirolimus ( know inhibitor mammalian target rapamycin ) metformin Concurrent combination antiretroviral therapy HIVpositive patient Concurrent enzymeinducing antiepileptic drug ( EIAEDs ) ( e.g. , phenytoin , carbamazepine , phenobarbital ) CYP3A4 inducer ( e.g. , rifampin Hypericum perforatum [ St. John 's wort ] ) Concurrent investigational commercial agent therapy treat patient 's malignancy Other concurrent investigational agent temsirolimus metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>